|
Anticancer Agent with N-Glycan Specificity
Application
An engineered protein for targeting disease-associated N-glycans.
Key Benefits
High affinity, pH insensitive, no cofactors required.
Applications in anticancer and antiviral therapeutics and research.
Can aid in manufacturing monoclonal antibodies with desired N-glycosylation properties.
Market Summary
Glycosylation involves post-translation...
Published: 12/5/2025
Contributor(s): Eric J. Sundberg, Diego Sastre, Maros Huliciak
|
|
Combinatorial Therapy for Preserving Muscle Mass During Weight Loss
Application
A combinatorial therapy to preserve muscle mass during semaglutide weight loss treatment.
Key Benefits
Preserves lean mass during semaglutide treatment in preclinical mouse models.
Increases overall fat loss without affecting food/water intake during semaglutide treatment in preclinical mouse models.
Market Summary
The prevalence...
Published: 12/5/2025
Contributor(s): Todd Golde, Yong Ran, Eric Krause, Annette De Kloet, Karen Scott
|
|
MVA and DNA Based SARS-CoV-2 Vaccines
Application
Modified Vaccinia virus Ankara (MVA)- and deoxyribonucleic acid (DNA)-based vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Key Benefits
Safety profile is known.
Demonstrated antiviral activity against related Coronaviruses.
Single dose of vaccination was shown to be effective against related Coronaviruses...
Published: 10/15/2025
Contributor(s): Rama Rao Amara, Sailaja Gangadhara
|
|
Vaccines and Antibody Therapeutics for HPV-related Cancers
Application
Treatment and prevention of HPV-induced malignancies.
Key Benefits
Identification of a protein expressed in a large number of HPV-induced cancers.
Antibodies have been generated that bind to the protein and potentially elicit an immune response to the cancer cells.
The antibodies can be used to develop new treatments and vaccines...
Published: 12/5/2025
Contributor(s): Rafi Ahmed, Andreas Wieland
|
|
A Predictive Marker and Treatment to Sensitize Multiple Myeloma Patients to Venetoclax (ABT-199)
Application
A marker that predicts Venetoclax (ABT-199) sensitivity that can also be targeted with a drug to help multiple myeloma patients.
Key Benefits
Marker that predicts if venetoclax will be an effective treatment in multiple myeloma patients.
A drug that targets venetoclax resistant multiple myeloma cells to improve treatment in patients.
Market...
Published: 2/28/2025
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
|
Frog Skin Peptides for Treatment of Zika Viruses
Application
A therapeutic peptide that treats Zika Virus.
Key Benefits
Potential therapeutic to fight against the growing threat of the Zika virus.
Peptide is fast acting and destroys Zika virions within 5 minutes of exposure.
Market Summary
Zika is an infectious disease spread primarily by Aedes mosquitoes and results in symptoms similar to...
Published: 11/3/2025
Contributor(s): Joshy Jacob, Song Lee, David Holthausen, Sanil George
|
|
Photocaged Cytokines for Cancer Immunotherapy
Application
Light-responsive cytokine prodrugs with controlled activation for improved cancer immunotherapy.
Key Benefits
Spatiotemporal control of therapeutic cytokine activation leads to controlled local activation and reduces off-target toxicity.
Prolonged circulation means less frequent dosing is required.
Biased activity towards CD8+ T-cells...
Published: 9/3/2025
Contributor(s): Erik Dreaden, Lacey Perdue, Priscilla Do
|
|
Live Attenuated Zika Virus Vaccines
Application
Yellow fever virus-based live attenuated Zika virus (ZIKV) vaccines.
Key Benefits
Reduces neurotropism from Zika virus.
High safety and immunogenicity of chimeric vaccines.
Market Summary
Zika virus (ZIKV) belongs to the flavivirus family of viruses, which include West Nile (WN), Japanese encephalitis (JE), yellow fever (YF), dengue...
Published: 2/13/2025
Contributor(s): Baek Kim
|
|
Therapeutic Compounds Inhibiting DUSP5 and DUSP6 for Cardiomyocyte Proliferation and Cardiac Regeneration
Application
Therapeutics using siRNAs and small molecules to treat congenital heart defect and myocardial injuries.
Key Benefits
Reactivates cardiomyocyte (CM) cell replication, allowing regeneration of heart muscle after cardiac injuries.
Therapeutic compounds may be administered for transient regeneration/repair of heart muscle after cardiac...
Published: 2/13/2025
Contributor(s): Ahsan Husain, Nawazish Naqvi
|
|
Combination Therapy for Increasing Venetoclax Sensitivity in Multiple Myeloma
Application
Marker and co-therapy that inhibits succinate dehydrogenase to increase patient response to venetoclax.
Key Benefits
Co-therapy increases MM sensitivity to venetoclax treatment.
Identifies patients who will respond to venetoclax therapy.
Market Summary
Multiple Myeloma (MM) is a cancer of plasma cells responsible for making antibody...
Published: 10/15/2025
Contributor(s): Malathy (mala) Shanmugam, Richa Bajpai
|
